Wegovy vs. Foundayo: Comparing the First 2 GLP-1 Weight Loss Pills

Until recently, glucagon-like peptide-1 (GLP-1) receptor agonists were only available as an injection. Now people can take these highly effective weight loss medications in a more convenient pill form. In late 2025 and early 2026, the U.S. Food and Drug Administration (FDA) approved two GLP-1 weight loss pills: oral semaglutide (Wegovy) and orforglipron (Foundayo).

Weight Loss: The Data

“At this time, there aren’t any published head-to-head obesity trials directly comparing oral semaglutide to orforglipron,” says Maria Teresa Anton, MD, a board-certified internal medicine physician who specializes in endocrinology, diabetes, and metabolism with Pritikin Longevity Center in Miami. But according to available data, oral Wegovy may be slightly more effective than Foundayo.

Secondary Benefits

These medications offer potential benefits beyond weight loss as well.

“Due to these findings, oral Wegovy would currently be my preferred choice when cardiovascular risk reduction is top priority,” says Anton, noting that both medications seem promising for people focused primarily on blood glucose control or creating modest improvements in blood pressure and cholesterol.

There’s early evidence to suggest that GLP-1 medications may help curb addictive behaviors as well, says Richard Frank, MD, the West Palm Beach, Florida–based chief medical officer for Vida Health, a medical weight loss program.

“There is also growing interest in whether GLP-1 medications may help with nicotine dependence, binge eating disorder, and other compulsive reward-driven behaviors,” says Anton. “Larger randomized controlled trials are still needed before these medications become [part of] evidence-based standards of care [for these uses].”

Side Effects

Both oral Wegovy and Foundayo can lead to similar gastrointestinal (GI) side effects, including nausea, diarrhea, constipation, and vomiting, says Anton. But research suggests these side effects are more common with oral Wegovy than Foundayo.

Convenience

While oral Wegovy and Foundayo are both pills, they’re administered differently, which may make Foundayo easier to stick with.

The Takeaway

• There are two FDA-approved oral GLP-1 weight loss medications, oral semaglutide (Wegovy) and orforglipron (Foundayo), with Wegovy showing slightly higher weight loss results than Foundayo.
• Both medications can improve heart and metabolic health markers like blood pressure and cholesterol, but oral Wegovy is specifically preferred for patients prioritizing cardiovascular risk reduction, such as preventing heart attacks or strokes.
• While both drugs can cause similar gastrointestinal side effects like nausea, these issues appear more frequently in clinical trial participants taking oral Wegovy than those taking Foundayo.
• Foundayo offers a significant convenience advantage because it can be taken with or without food, whereas oral Wegovy requires a strict routine of taking the pill on an empty stomach followed by a 30-minute fast.